Buscar
Agenus Inc
AGENAñadir a la lista de seguimiento
6.600USD
+0.470+7.67%
Cierre 07-28 16:00（ET）Cotizaciones retrasadas 15 min
254.24MCap. mercado
3.20P/E TTM
Más Datos de Agenus Inc Compañía
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Información de Agenus Inc
Símbolo de cotizaciónAGEN
Nombre de la empresaAgenus Inc
Fecha de salida a bolsaFeb 04, 2000
Director ejecutivoArmen (Garo H)
Número de empleados316
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 04
Dirección3 Forbes Rd
CiudadLEXINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02421-7305
Teléfono17816744400
Sitio Webhttps://agenusbio.com/
Símbolo de cotizaciónAGEN
Fecha de salida a bolsaFeb 04, 2000
Director ejecutivoArmen (Garo H)
Ejecutivos de Agenus Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
47.55K
+17.98%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
47.55K
+17.98%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Agenus Inc?
Los cinco principales accionistas de Agenus Inc son: Mr. Thomas L. (Tom) Harrison, Ph.D.
¿Cuántas instituciones poseen acciones de Agenus Inc (AGEN)?
A fecha de 2026Q1, 275 instituciones poseen acciones de Agenus Inc, con un valor de mercado combinado de aproximadamente 10.91M, lo que representa el 26.27% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -968401.00.
¿Cuál es la mayor fuente de ganancias de Agenus Inc?
El 2026Q1, el segmento empresarial Non-cash royalty revenue generó la ganancia más alta para Agenus Inc, ascendiendo a 108.59M y representando el 95.09% de la ganancia total.